1 / 19

Presenter: Dr Julius Oyugi

CIHR team grant in HIV vaccine discovery: novel mechanisms and strategies of protection University of Toronto KAVI University of Nairobi. Presenter: Dr Julius Oyugi. HIV Vaccine Team. University of Toronto Mario Ostrowski [PI] Tania Watts Jen Gommerman Goetz Erhardt Rupert Kaul

xue
Download Presentation

Presenter: Dr Julius Oyugi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CIHR team grant in HIV vaccine discovery: novel mechanisms and strategies of protectionUniversity of TorontoKAVI University of Nairobi Presenter: Dr Julius Oyugi

  2. HIV Vaccine Team University of Toronto • Mario Ostrowski[PI] • Tania Watts • Jen Gommerman • Goetz Erhardt • Rupert Kaul • James Rini • Dana Philpott University of Nairobi • Walter Jaoko[PI] • OmuOnzala. • Julius Oyugi

  3. PRINCIPLES • Need for “Back to Basics” approach. • Focus on mucosal sites. • Target HIV immune responses via T cells, B cells and Innate cells.

  4. Nature of research collaboration. • Grant uses an iterative approach • Yearly meetings of all members • Cross-fertilization of trainees • Project is primarily discovery and pre-clinical • Industrial partners to be based on promising discoveries.

  5. Team grant Themes Theme 1: Optimizing CD8 T cell memory for prophylactic or therapeutic immunization. • An ALVAC strategy[weakly immunogenic and potentially efficacious]. • A VZV strategy [a persistently reactivating immunogen]. Theme #2: Optimizing and targeting mucosal antibody responses.

  6. Aim 1: Pre-clinical development of a canarypox (ALVAC) expressing HIV antigens and TNF-SF (tumor necrosis factor superfamily) molecules. • CTL vaccines based on DNA and pox virus vectors do not provide long lived memory T cell responses in humans. • Members of the TNFSF can enhance HIV specific CTL responses by their stimulatory effects on dendritic cells or CD4+ T cells.

  7. Plan • Develop ALVAC-SIV-gpe-TNSF vaccine construct • Carry out non-human primate studies

  8. Aim 2: Pre-clinical development of immunotherapeutic approaches targeting costimulatory and coinhibitory pathways to improve T cell function in HIV infection. • CTL are exhausted in chronic virus infections. • Build on team members Watts, Ostrowski work: • Tim-3 upregulation and TRAF-1 downregulation are markers of CD8 dysfunction during chronic viral infection • Evaluation of candidate co-stimulatory molecules to improve T cell function including CD40L, 41-BBL, Tim-3 blockade[mice model].

  9. Aim 3: Determining the feasability of a persistent replicating virus vector for HIV vaccine development: the role of pre-existing vector immunity on mucosal T cell immunity and activation. • Current DNA/virus vector primer are limited in maintaining long term effector CTL. • Emerging evidence suggests that virus vectors that can continue to induce persistent effector CTL may be preferable[Louis Picker et al, 2011].

  10. VZV based Vaccine as a vector Goal is to determine whether a VZV based vaccine could; • Induce mucosal T cell immunity even in the presence of VZV sero-positivity. • To assess the activation state of mucosal sites post VZV vaccination, particularly in those who are VZV sero-positive.

  11. Team member McDonald has developed preclinical HIV vaccine candidates based on persistent CMV and VZV vectors. • Plan: • Field work in Kenya evaluating T cell systemic and mucosal immune responses after administration of a licensed VZV vaccine[Team member Walter Jaoko].

  12. Aim # 4: Exploring B cells as key cellular players in controlling HIV propagation within mucosal tissues • It is uncertain if B cells are actively recruited to sites of viral replication in the mucosa, and if so, what types of B cells congregate around active foci of viral replication.

  13. Team member Gommerman is B cell immunologist • PLAN: • Evaluating B cell subsets in human gut and genital mucosa tissues • Evaluating TNF/iNOS-producing plasma cells at mucosal sites and their role in viral control • Evaluating B cell exhaustion and how to reverse it.

  14. Aim 5: To investigate the feasibility of blocking the HIV Env/ T cell integrinα4β7/b1 interaction as a strategy to reduce mucosal acquisition of HIV. • The role of α4β7 in HIV pathogenesis • Homing marker for effector T cells to the gut. • It is capable of binding HIV gp120. • Its expression is associated with increased susceptibility to HIV infection.

  15. Team member Dr. Kaul has expertise in mucosal • immunology of gut / genital tract • PLAN: • Assess expression of α4β7 and ligandMAdCAM in genital tissues (cervix, foreskin). • Assess importance of α4β7: HIV target cell susceptibility at mucosal sites. • Work with team member Rini to develop small molecule inhibitors.

  16. Aim 6: Nod agonists as vaccine adjuvants Team member Philpott is Nod expert Test ability of candidate NLR agonists to enhance antibody responses at the mucosal level. Progress: Have begun testing Nod 2 agonist (MDP) and a novel nod agonist (AHL) in a DNA vaccine and protein vaccine approach using gp120 in Balb/C mice.

  17. Aim 7: Development and standardization of mucosal immune assays focused on B cell responses to be applied to vaccination studies in the Kenyan cohort. • Team member Dr Oyugi and Prof Anzala PLAN: • Assess B cell immunity at the mucosal surface • Development of HIV Ab ELISA using envelopes from early infection, IgG, IgA • B cell ELISpot assay from mucosal surfaces: IgG, IgA Progress: Obtained Envclade A and C during early infection • KAVI personnel training at UT site

  18. Obstacles so far • Purchasing equipment and transporting to UN is problematic • Protocol development requires REB approval at both sites • No indirect costs permitted by funder on funds sub-contracted to UN site.

  19. ACKNOWLEDGEMENTS • UOT TEAM: [Mario Ostrowski,Tania Watts, • Jen Gommerman,GoetzErhardt, • Rupert Kaul, James Rini, • Dana Philpott]. • UON TEAM [Walter Jaoko, OmuOnzala, • Julius Oyugi]. • CIHR AND GHRI

More Related